Factors That Improve Progesterone Absorption
Taking oral micronized progesterone with food significantly increases its bioavailability compared to the fasting state. 1
Route-Specific Absorption Optimization
Oral Administration
Micronization is the single most important factor for oral progesterone absorption. The FDA label explicitly states that "the oral bioavailability of progesterone is increased through micronization." 1
Food co-administration enhances bioavailability when taking the standard 200 mg dose; patients should take oral progesterone capsules with meals rather than on an empty stomach. 1
Oil-based vehicles further optimize absorption: micronized progesterone suspended in oil achieves mean peak serum concentrations of 30.3 ± 7.0 ng/mL at 2.0 ± 0.3 hours post-administration, significantly higher than other formulations (plain milled: 9.6 ± 2.5 ng/mL; micronized without oil: 13.2 ± 2.4 ng/mL). 2
Particle size reduction through micronization increases surface area and dissolution rate, directly improving gastrointestinal absorption regardless of vehicle. 2
Cytochrome P450 3A4 inhibitors (such as ketoconazole) block hepatic metabolism of progesterone and may increase bioavailability, though the clinical relevance remains uncertain. 1
Vaginal Administration
Vaginal delivery bypasses first-pass hepatic metabolism and provides sustained endometrial tissue concentrations with lower systemic exposure. 3, 4
Absorption is comparable to oral dosing for endometrial protection: 200 mg vaginal progesterone daily for 12–14 days per month achieves equivalent endometrial effects as the same oral dose. 4, 5
Avoid sexual intercourse within 10 hours of vaginal progesterone administration: intercourse significantly reduces serum progesterone concentrations (P = 0.0075) and may compromise therapeutic efficacy. 6
Timing optimization: vaginal progesterone should be administered at bedtime to maximize absorption time before potential physical displacement. 6
Transdermal Administration
Percutaneous progesterone absorption correlates strongly with concurrent transdermal estradiol absorption (correlation coefficient 0.53, P < 0.0001), suggesting shared mechanisms of dermal penetration. 7
Sustained serum concentrations are achieved after 2 weeks of daily application (30 mg/day), with levels maintained for at least 8 hours post-application. 7
Dose-proportional response: doubling the daily dose from 30 mg to 60 mg produces appropriate increases in serum progesterone after 4 weeks of application. 7
Individual variability is substantial (mean concentrations ranging 1.6–3.3 ng/mL across subjects), but consistency within a given patient is high throughout treatment. 7, 8
No accumulation occurs with chronic use: plasma progesterone levels plateau after 12 weeks and remain stable through 48 weeks of continuous application. 8
Formulation-Specific Factors
Micronized vs. Non-Micronized
All micronized formulations (whether in oil, plain capsules, or enteric-coated) produce significant serum progesterone elevations, whereas non-micronized preparations show markedly lower absorption. 2
Enteric coating does not improve absorption beyond standard micronization: micronized progesterone in enteric-coated capsules achieves peak levels of 11.2 ± 3.0 ng/mL at 4.1 ± 0.7 hours, similar to plain micronized formulations. 2
Polymorph Considerations (Research Context)
Form II polymorph of progesterone demonstrates higher aqueous solubility than Form I, which may enhance absorption in specialized formulations. 9
Hydroxypropyl methylcellulose acetate succinate (HPMCAS) as an excipient temporarily enables supersaturated states and prevents polymorphic transformation during processing, potentially improving dissolution. 9
Clinical Optimization Algorithm
| Clinical Goal | Recommended Strategy | Evidence |
|---|---|---|
| Maximize oral absorption | Micronized progesterone 200 mg with food | [1,2] |
| Minimize systemic side effects | Switch from oral to vaginal 200 mg daily | [4,5] |
| Optimize transdermal delivery | Apply at consistent time daily; combine with transdermal estradiol | [7,8] |
| Ensure vaginal efficacy | Administer at bedtime; avoid intercourse for 10 hours | [6] |
| Address poor oral absorption | Consider oil-based micronized formulation | [2] |
Common Pitfalls to Avoid
Do not administer oral progesterone on an empty stomach when absorption optimization is critical; food co-administration is FDA-documented to enhance bioavailability. 1
Do not assume vaginal and oral routes are interchangeable for systemic effects: vaginal administration produces lower systemic concentrations but adequate local endometrial tissue levels. 3
Do not overlook sexual activity timing with vaginal progesterone: intercourse within 10 hours reduces absorption and may compromise luteal phase support or endometrial protection. 6
Do not use non-micronized progesterone for oral administration: micronization is essential for clinically meaningful absorption. 1, 2
Do not expect immediate steady-state concentrations with transdermal delivery: sustained levels require at least 2 weeks of consistent daily application. 7